eCite Digital Repository

CCR6–CCL20-Mediated Immunologic Pathways in Inflammatory Bowel Disease


Ranasinghe, R and Eri, R, CCR6-CCL20-Mediated Immunologic Pathways in Inflammatory Bowel Disease, Gastrointestinal Disorders, 1, (1) pp. 15-29. ISSN 2624-5647 (2019) [Review Several Works]

PDF (Review on CCR6 -CCL20 Signalling pathways, School of Health)
Pending copyright assessment - Request a copy

DOI: doi:10.3390/gidisord1010003


Inflammatory bowel disease (IBD) has evoked significant interest in human immunobiology given its tactical immune evasion methodologies resulting in acute immune destabilization. IBD comprising Crohn’s disease and Ulcerative colitis manifests as chronic inflammation in the gut mucosa, leading to complexities involving immune dysregulation in the T helper lymphocyte arm, effecting disease pathogenicity. The mucosa of the alimentary canal is constantly exposed to a myriad of food antigens and luminal microorganisms for which a consistent host-protective mechanism is operative in healthy people. Lowered mucosal immune expression which allows penetration of the epithelial barrier by infective pathogenic microbes elicits both innate and adaptive immune responses in the gut, culminating in aberrant intestinal inflammation. Interestingly, the IBD leukocyte repertoire is significantly entwined with chemokine-assisted chemotactic navigation into the sites of inflammation, which is also thought to generate favorable immune-suppressive responses. The functions of the cognate chemokine receptor, CCR6, which binds with its unique ligand CCL20, are expected to tilt the balance between upregulation of homeostatic tolerance and inflammatory pathophysiology. This review aims to critically examine the CCR6-driven immune pathways: TH1/TH2, TH1/TH17, TH17/Treg, IL-23/IL-17, Akt/ERK-1/2, ILC3, and TH9/TH2 for systematic investigation of its underlying mechanisms in the future and to underpin its importance in resolving IBD pathology. Thus, CCR6 occupies an exclusive position in gut immunology which renders it an invaluable therapeutic tool for the production of novel medicaments to treat IBD.

Item Details

Item Type:Review Several Works
Keywords:Chemokine Receptor 6, Signalling pathways, Infectious/Autoimmune diseases
Research Division:Biomedical and Clinical Sciences
Research Group:Immunology
Research Field:Cellular immunology
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Ranasinghe, R (Ms Hewausaramba Ranasinghe)
UTAS Author:Eri, R (Associate Professor Raj Eri)
ID Code:129580
Year Published:2019
Web of Science® Times Cited:4
Deposited By:Health Sciences
Deposited On:2018-12-07
Last Modified:2019-01-09

Repository Staff Only: item control page